ArticleCancer research2016
The Cancer Stem Cell Fraction in Hierarchically Organized Tumors Can Be Estimated Using Mathematical Modeling and Patient-Specific Treatment Trajectories.
Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 75 citations in OpenAlex.
- Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.Haematologica · 2018Trial
- Dedifferentiation-driven oncogenic stemness promotes tumor-sustaining adaptability in the intestinal epithelium.Cell death & disease · 2026Article
- Stochastic journeys of cell progenies through compartments and the role of self-renewal, symmetric and asymmetric division.Scientific reports · 2024Article
- Measures of genetic diversification in somatic tissues at bulk and single-cell resolution.eLife · 2024Article
- Cells and material-based strategies for regenerative endodontics.Bioactive materials · 2022Review
- A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells.Nature genetics · 2022Article
- Data-Driven Discovery of Mathematical and Physical Relations in Oncology Data Using Human-Understandable Machine Learning.Frontiers in artificial intelligence · 2021Article
- Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.Cancer research · 2020Article
- Evidence for hypoxia increasing the tempo of evolution in glioblastoma.British journal of cancer · 2020Article
- Inferring Tumor Proliferative Organization from Phylogenetic Tree Measures in a Computational Model.Systematic biology · 2020Article
- An Optimal Control Framework for the Automated Design of Personalized Cancer Treatments.Frontiers in bioengineering and biotechnology · 2020Article
- Engineered 3D Model of Cancer Stem Cell Enrichment and Chemoresistance.Neoplasia (New York, N.Y.) · 2019Article
- Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.Cancer research · 2019Article
- Illuminating the Numbers: Integrating Mathematical Models to Optimize Photomedicine Dosimetry and Combination Therapies.Frontiers in physics · 2019Article
- Mathematical modeling reveals the factors involved in the phenomena of cancer stem cells stabilization.PloS one · 2019Article
- Effect of cellular de-differentiation on the dynamics and evolution of tissue and tumor cells in mathematical models with feedback regulation.Journal of theoretical biology · 2018Article
- gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML.Cell death & disease · 2018Article
- Analysis of MicroRNA-mRNA Interactions in Stem Cell-Enriched Fraction of Oral Squamous Cell Carcinoma.Oncology research · 2018Article
- Modelling of the SDF-1/CXCR4 regulatedPeerJ · 2018Article
- A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment.PLoS computational biology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Many tumors are hierarchically organized and driven by a subpopulation of tumor-initiating cells (TIC), or cancer stem cells. TICs are uniquely capable of recapitulating the tumor and are thought to be highly resistant to radio- and chemotherapy. Macroscopic patterns of tumor expansion before treatment and tumor regression during treatment are tied to the dynamics of TICs. Until now, the quantitative information about the fraction of TICs from macroscopic tumor burden trajectories could not be inferred. In this study, we generated a quantitative method based on a mathematical model that describes hierarchically organized tumor dynamics and patient-derived tumor burden information. The method identifies two characteristic equilibrium TIC regimes during expansion and regression. We show that tumor expansion and regression curves can be leveraged to infer estimates of the TIC fraction in individual patients at detection and after continued therapy. Furthermore, our method is parameter-free; it solely requires the knowledge of a patient's tumor burden over multiple time points to reveal microscopic properties of the malignancy. We demonstrate proof of concept in the case of chronic myeloid leukemia (CML), wherein our model recapitulated the clinical history of the disease in two independent patient cohorts. On the basis of patient-specific treatment responses in CML, we predict that after one year of targeted treatment, the fraction of TICs increases 100-fold and continues to increase up to 1,000-fold after 5 years of treatment. Our novel framework may significantly influence the implementation of personalized treatment strategies and has the potential for rapid translation into the clinic. Cancer Res; 76(7); 1705-13. ©2016 AACR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.